Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study-Reference-Cited by-同舟云学术

Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study

Published:2022-11-16 Issue:8 Volume:76 Page:1500-1503
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Birabaharan Morgan¹,Hill Eddie¹,Begur Maedha¹,Kaelber David C²³,Martin Thomas C S¹⁴,Mehta Sanjay R¹⁴

Affiliation:

1. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego , La Jolla, California , USA

2. The Center for Clinical Informatics Research and Education, The MetroHealth System , Cleveland, OH , USA

3. Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University , Cleveland, OH , USA

4. San Diego Veterans Affairs Healthcare System , San Diego, California , USA

Abstract

Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac894/47763262/ciac894.pdf

Reference9 articles.

1. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19—COVID-NET, 10 States, March 2020–February 2022;Singson;MMWR Morb Mortal Wkly Rep,2022

2. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19;Levin;N Engl J Med,2022

3. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial;Montgomery;Lancet Respir Med,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness and Safety of Tixagevimab–Cilgavimab: A Target Trial Emulation Study;Drug Safety;2024-06-25

2. COVID-19 Treatments: Then and Now;The Journal of Allergy and Clinical Immunology: In Practice;2023-11

3. COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023;Infectious Diseases and Clinical Microbiology;2023-09-30

4. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan;International Journal of Hematology;2023-09-25

5. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection;Cureus;2023-07-03